期刊
BRITISH JOURNAL OF CANCER
卷 111, 期 8, 页码 1532-1541出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2014.444
关键词
breast cancer; genomics; subtypes; intrinsic; basal like; chemotherapy; neoadjuvant
类别
资金
- NCI Breast SPORE program [P50-CA58223-09A1]
- Breast Cancer Research Foundation
- National Cancer Institute (NCI) Strategic Partnering to Evaluate Cancer Signatures [U01 CA114722-01]
- Sociedad Espanola de Oncologia Medica
- FEDER [RETICC-RD12/0036/0051, RD12/0036/0042, RD12/0036/0076, RD12/0036/0070]
- Instituto de Salud Carlos [III-PI13/01718]
- Banco Bilbao Vizcaya Argentaria (BBVA) Foundation
- Alliance Statistics and Data Center [U10-CA33601]
- [RO1-CA138255]
- Cancer Research UK [15955] Funding Source: researchfish
Background: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). Methods: Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated. Results: Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival. Conclusions: The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据